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Abstract
Background: The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity
is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the
two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent
infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the
World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria.
Methods: We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6–59
months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT).
Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine
(DHAPQ), and actively followed up for 28 days.
Findings: Among 220 patients enrolled, 217 (98.6 %) were assigned an efficacy outcome and 218 (99.1 %) were assessed for
safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70 %, 74/110, HR = 3.9; 95 %
CI: 2.4–6.7, p,0.0001) and AL (60%, 21/35, HR= 3.3; 95 % CI: 1.8–6.3, p,0.0002), compared to DHAPQ (25%, 18/72).
Recrudescence tended to be lower in the DHAPQ (1%, 1/72) than in the quinine (7%, 8/110) or AL (6 %, 2/35) group, though
it was not statistically significant. No serious adverse events were reported.
Conclusion: Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative
ACT rather than with quinine.
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Introduction
Most malaria endemic countries have deployed artemisinin
combination therapy (ACTs) as first line regimens for the
treatment of uncomplicated falciparum malaria [1]. ACTs are
highly efficacious, well tolerated, reduce gametocyte carriage and
could, if well used and deployed, delay the emergence and spread
of antimalarial drug resistance [2,3]. Where malaria transmission
is intense, recurrent infections, i.e. peripheral infections (with or
without fever) following the treatment of primary episodes, are a
common occurrence [4,5]. Though a recurrent infection may be
either a recrudescence (same infection as the primary one) or a
new infection, such information is not immediately available for
managing the patient as the necessary molecular analysis of the
parasite isolates is done later in a well-equipped laboratory.
Patients with recurrent infections are usually given the second line
treatment which should be safe and efficacious in case of resistance
to the treatment used for the primary episode. In several sub-
Saharan African countries, the second line treatment is oral
quinine [1,6], a policy not consistent with the current WHO
recommendations to use combination therapy for uncomplicated
malaria [1,7]. There is little or no information available on ACTs
used as rescue treatments. Therefore, a study aiming at
establishing the safety and efficacy of two different ACTs when
used as rescue treatment as compared to quinine, the treatment
routinely used for this purpose, was carried out in Tororo,
Uganda, an area of intense malaria transmission. Results are
reported below.
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Methods
Study design
This nested study was carried out in Tororo, Uganda, one of the
sites participating in a large multi-centre trial (12 sites spread over
7 countries) on the safety and efficacy of four ACTs (artemether-
lumefantrine-AL, amodiaquine-artesunate-ASAQ, dihydroartemi-
sinin-piperaquine-DHAPQ, and chlorproguanil-dapsone and ar-
tesunate-CD+A). Details of the multi-centre trial are published
elsewhere [8]. Briefly, children 6–59 months old at the time of
inclusion were randomised and treated with one of the four study
drugs, followed up actively for 28 days (first active follow up) and
then passively for the next 6 months. After the first 28 days, if they
experienced a second malaria episode, they were treated with the
same ACT used for the first episode and actively followed up for
28 additional days (second active follow up). Each site tested three
out of the four ACTs. In case of treatment failure during the first
or second active follow up, patients were given the rescue therapy
according to the prevailing national recommendations (quinine for
most study sites). At Tororo, the site where this nested study was
carried out, the study treatments for the primary episode were AL,
CD+A and DHAPQ. Patients with late treatment failure (after day
3 of the follow up and up to day 28) during the first or second
active follow up were recruited into the nested study and
randomised to either quinine (the recommended second line) or
an ACT- either AL or DHAPQ. Group allocation depended on
previous treatment and different randomization processes were
employed to achieve this. Children who got AL in the first study
were randomized to either the QN or DHAPQ arm, those who
got DHAPQ were randomised to the AL or QN arms and those
who got CD+A were randomised to either the QN, AL and
DHAPQ arm. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1
Study site
The nested study was conducted between December 2007 and
April 2009 at Nagongera Health Centre, in Tororo district,
Uganda, an area of intense perennial malaria transmission (annual
entomological inoculation rate estimated at 562 infective bites per
person per year) [9]. The main and nested studies were approved
in Uganda by the Makerere University Faculty of Medicine
Research and Ethics committee and by the Ugandan National
Council for Science and Technology, and in Belgium by the
Institutional Review Board of the Institute of Tropical Medicine
and by the Ethical Committee of the University Hospital in
Antwerp. The study approvals are available as supporting
information; see File S2 and S3.
Participants
Patients from the main trial were included in this nested study if
they had late treatment failure (recurrent infection with or without
fever) between day 4 and day 28 of the two active follow ups. The
participant selection criteria in the main study have been reported
elsewhere [1,8]. Children experiencing an early treatment failure,
severe malaria or having danger signs, or those with history of
hypersensitivity to the study drugs were excluded and treated with
parenteral quinine [1,10,11]. Caregivers were explained the study
objectives and procedures, and asked to provide a written
informed consent.
Baseline Evaluation, Randomization and Treatment
At enrolment, patient’s symptoms were evaluated. Temperature
(axillary) and weight were measured and a focused physical
examination was performed. A thick and thin blood smear for
parasitaemia and a blood sample on filter paper (Whatman 3MM)
for later molecular analysis were collected before treatment.
Patients were randomly assigned to receive either quinine or one
of the two ACTs, (AL or DHAPQ). For the latter, to avoid giving
the same ACT administered for the primary episode as rescue
treatment, patients having received AL as primary treatment were
treated with DHAPQ as rescue treatment and vice versa; patients
having received CD+A were randomized to one of the two ACTs
(Figure 1). A randomization list was computer generated by a
member of the project not directly involved in patient manage-
ment; sequentially numbered, sealed envelopes containing the
treatment assigned were prepared according to the randomization
lists. The study nurse assigned treatment numbers sequentially and
allocated treatment by opening the envelope corresponding to the
treatment number. A second randomisation list was used to
randomise patients initially treated with CD+A to either AL or
DHAPQ. Only the study nurse had access to the sealed treatment
randomization list though, given the variation in appearance, taste
and dosing, the other research staff may have known to which arm
children were assigned. Molecular analysis of the parasite isolates
was carried out blindly, without knowing the treatment received
by the patient. Supervised treatment allocation and administration
of medications was performed by the study nurse who adminis-
tered all medications orally as follows: AL (Coartem, Novartis,
20 mg artemether/120 mg lumefantrine tablets), administered
according to the body weight as : one (5–14 kg), two (15–24 kg), or
three (25–34 kg) tablets given twice daily for 3 days; DHAPQ
(Eurartesim, Sigma-Tau, Italy, dihydroartemisinin (DHA)
20 mg+piperaquine phosphate (PQP) 160 mg and DHA
40 mg+PQP 320 mg tablets), given once daily for three days, at
the standard dosage of 2.25 mg/kg and 18 mg/kg per dose of
DHA and PQP, respectively, rounded up to the nearest J tablet.
Participants in the quinine arm received a seven day course of
quinine sulphate as 10 mg/kg body weight per dose three times
daily. Quinine sulphate was provided as 300 mg tablets (Rene
Pharmaceutical, Kampala, Uganda); the quality of the drug was
certified by the Uganda National Drug Authority. We used a pill
cutter to ensure the tablet fractions were as close to the nearestJ
tablet as possible. The administration of all doses was directly
observed. Patients were kept for 30 minutes after treatment and
the dose was re-administered if vomiting occurred. Patients who
vomited persistently were given parenteral quinine. All patients
were provided with a 3-day supply of paracetamol for the
treatment of febrile symptoms. Patients with haemoglobin
,10?0 g/dL were treated with ferrous sulphate for 14 days and
given mebendazole if they were over one year of age and had not
been treated in the previous 6 months. All patients who developed
severe/complicated malaria during active follow-up were treated
with parenteral quinine. Patients randomised to ACT who failed
therapy were treated with quinine 10 mg/kg orally three times a
day for 7 days. Patients who failed quinine therapy were treated
with artesunate (2 mg/kg once a day) and clindamycin (10 mg/kg
twice a day) for 7 days.
Follow-up Procedures
At enrolment, children’s parents or guardians were asked about
use of other medications and presence of common symptoms.
Axillary temperature and weight were recorded, and a physical
examination performed. A blood sample for thick and thin blood
smears, hemoglobin assessment and later molecular analysis (on
filter paper) was collected by fingerprick. Similarly, at follow up
visits scheduled for Days 1, 2, 3, 7, 14, 21 and 28, a standardized
history was collected and physical examination performed. At each
Treatment of Recurrent Malaria
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visit, including unscheduled ones, blood for thick blood smears and
later genotyping was collected (by finger prick). Hemoglobin
measurement was repeated on day 28 or the day of late clinical
failure. Patients were encouraged to attend the clinic at any time if
ill. Patients not attending the clinic at the scheduled visits were
actively followed up at home.
Laboratory Evaluations
Thick and thin blood smears were stained with 2% Giemsa for
30 minutes. Parasite density was determined by reading the thick
blood smear and counting the number of asexual parasites per 200
white blood cells (WBCs), assuming a WBC count of 8,000/ml.
Slides were considered negative if no parasite was detected after
reading 100 high-powered fields. Presence of gametocytes was also
recorded. Thin blood smears were reviewed for non-falciparum
infections. Two microscopists independently read all slides and
parasite densities were calculated by averaging the two counts.
Readings with discordant results (difference in species diagnosis,
difference in parasite density of .50%, or any difference that
affected recruitment or study outcome) were re-examined by a
third microscopist; the parasite density was calculated by
averaging the two closest densities while the final parasite species
was determined by the two concordant reads. Hemoglobin
measurements were made using a portable spectrophotometer
(HemoCue, A¨ngelholm, Sweden).
Molecular genotyping was carried out at the Institute of
Tropical Medicine, Antwerp, Belgium, on samples collected from
patients with late treatment failure to discriminate between a
recrudescent and a new infection. Parasite deoxyribonucleic acid
(DNA) was isolated from filter paper blood samples collected at
enrolment and on the day of recurrent parasitemia using chelex
extraction. Genotyping was done according to international
recommendations [12]. The DNA was purified as previously
described [13] and three polymorphic genetic markers were
genotyped sequentially, starting with glutamate rich protein
(GluRP), followed by merozoite surface protein-2 (MSP2), and
ending with merozoite surface protein-1 (MSP1). Capillary
electrophoresis was used for MSP2. Whenever a genetic marker
showed a new infection, (no common allele between day of
recurrent infection and day 0) this was taken as the final result and
the analysis was stopped. For samples showing a recurrent
infection, (at least one identical allele between day 0 and day of
recurrent infection) the analysis was carried out until MSP1. If the
latter showed also at least one identical allele between day of
recurrent infection and day 0, then the infection was classified as a
recrudescence [12]. All results were double read and discrepancies
resolved. The InGenius Gel Documentation and Analysis system
Standard Operating Procedure (SOP) is available as supporting
information; see File S1.
Objectives
The objectives of the study were to compare the safety and
efficacy of quinine with that of two other ACT, i.e. AL or
DHAPQ, when used as rescue treatment for late treatment failure
(clinical or parasitological) following a primary episode of
uncomplicated malaria.
Outcomes – Efficacy
Treatment outcomes were classified according to the WHO
guidelines for areas of intense transmission as adequate clinical
and parasitological response (ACPR), early treatment failure
(ETF), late clinical failure (LCF), and late parasitological failure
(LPF) [11]. Failure was defined as the sum of ETF, LCF and LPF.
Patients were not assigned an efficacy outcome for the following
reasons: 1) administration of antimalarial drugs outside the study
protocol; 2) withdrawal of consent; and 3) loss to follow-up.
Day 28 treatment outcomes were adjusted to distinguish
recrudescent and new infections using molecular genotyping
based on GLURP, MSP2 and MSP1 polymorphisms. Recrudes-
cence was defined by a paired sample having at least one identical
allele present on each of the three loci. A new infection was
classified as infection with all alleles different in at least one locus.
When no amplification was observed for either of the paired
samples, the outcome was classified as indeterminate.
The primary efficacy endpoint was the clinical and parasito-
logical outcome at day 28, unadjusted and adjusted by genotyping.
Secondary efficacy endpoints included, fever and parasite clear-
ance, gametocytaemia (prevalence and density) at day 7, 14, 21
and 28, haemoglobin changes between Day 0 and Day 28 or the
day of treatment failure, and incidence of adverse events.
Outcomes - safety
Safety outcomes included risk of adverse events. At each follow-
up visit, any new or worsening event and laboratory results were
assessed. An adverse event was defined as any untoward medical
occurrence, irrespective of its relationship to the study medications
(Guidance for Industry Good Clinical Practice: Consolidated
Guidance [ICH E6], April 1996). All events were graded by
severity (none, mild, moderate, severe, life-threatening) and
relationship to study treatment was classified as none, unlikely,
possible, probable, or definite using WHO (toxicity grading scale
for determining the severity of adverse events) and National
Institute of Health (paediatric toxicity tables, May 2001) guide-
lines. A serious adverse event was defined as any event that
resulted in inpatient hospitalization, death, life threatening
experience, persistent/significant disability, or specific medical/
surgical intervention to prevent serious outcome.
Sample size
The study was designed to test the hypothesis that treatment
with AL or DHAPQ would change the risk of recurrent
parasitaemia (unadjusted by genotyping) after 28 days of treatment
compared to Quinine. The main study included 510 children (170
per arm) with uncomplicated malaria. It was expected that about
half of them (230) between days 4 and 28 would need rescue
Figure 1. The study design.
doi:10.1371/journal.pone.0053772.g001
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treatment as this is an area of high transmission [14] and be
randomized to either quinine or one of the two ACT. Assuming
50% of children in the ACT arms would experience an unadjusted
treatment failure compared to 60% or more in the quinine arm,
we would be able to detect, with 80% power and 5% level of
significance, a significant difference between the treatment groups.
Statistical Methods
Efficacy and safety data were evaluated using an intention-to-
treat analysis, including all patients with falciparum malaria
randomized to one of the study treatments. Data were double-
entered (EpiInfo 6?04H, Centers for Disease Control and
Prevention, Atlanta, GA, USA), verified, and analyzed using
Stata version 10?0 (Stata Corporation, College Station, TX, USA).
Parasite densities were normalized using logarithmic transforma-
tion. Risks of treatment failure were estimated using the Kaplan-
Meier product limit formula. Data were censored for patients who
did not complete follow-up or were reinfected with non-falciparum
species. For the polymerase chain reaction (PCR)-adjusted ACPR,
new Plasmodium falciparum infections detected on the basis of
genotyping were also censored. Comparisons of treatment efficacy
were made using a Cox proportional hazards model. We applied a
Bonferroni correction to mitigate the probability of observing a
significant difference by chance. With three comparisons, a p-
value less than 0.017 (0.05/3) was considered significant.
Results
Patient Characteristics
Among the 220 eligible patients, two were excluded because
they had a P. ovale infection and one was lost to follow up (Figure 2).
The remaining 217 patients had an efficacy outcome. The three
treatment group were comparable for the baseline characteristics
though children randomised to AL seemed to have a lower
parasite density and less fever (Table 1).
Primary efficacy outcomes
All 217 patients with efficacy outcomes were included in the
analysis. No ETF was detected (Table 2). Almost 70% (74/110) of
children in the quinine arm had a recurrent infection as compared
to 60% (21/35) in the AL and 25% (18/72) in the DHAPQ arms
(Table 2). Both quinine (HR=3.9; 95%CI: 2.4–6.7)(p,0.0001)
and AL (HR=3.3; 95%CI: 1.8–6.3)(p,0.0002) had a significantly
higher risk of recurrent infection as compared to DHAPQ
(Table 3). No significant difference in recurrent infection was
found between quinine and AL (p = 0.4) (Table 3). Most recurrent
infections were identified as new infections. Though the PCR-
adjusted treatment failure tended to be lower in the DHAPQ (1%,
1/72) than in the quinine (7%, 8/110) and AL (6 %, 2/35) groups,
it did not reach statistical significance (Table 3). The rate of
recurrent infections was lower and occurred later in the DHAPQ
treatment group (Figure 3). The baseline parasite density and
treatment allocation for the primary malaria episode had no
influence on treatment outcome (data not shown).
Secondary efficacy outcomes
Patients treated with DHAPQ experienced less rapid resolution
of fever compared to those treated with AL. However, by Day 3
fever had resolved in the majority of patients, regardless of
treatment group. The percentage of children with parasitaemia at
Day 2 was significantly lower in the ACT groups as compared to
quinine, and among the ACT, DHAPQ performed significantly
better than AL (Table 4). Nevertheless, at Day 3, none of the
children treated with an ACT had a detectable parasitaemia.
Adverse events were of mild or moderate severity and most of
them were consistent with malaria symptoms. Cough, anorexia
and diarrhoea were the most common, followed by abdominal
pain, weakness and vomiting (Table 4). Abdominal pain was
reported only among children treated with DHAPQ while
weakness occurred more frequently in the quinine group. Children
treated with ACTs had also a higher risk of vomiting as compared
to quinine (Table 4). No serious adverse event was observed.
The proportion of children with anaemia (haemoglobin of
,10?0 g/dL as per the Integrated Management of Childhood
Illness guidelines) decreased in all treatment groups between Day 0
and Day 28 (quinine 24.3% to 9.8%, AL 25.7% to 5.6%, DHAPQ
18.3% to 6.1%). The mean haemoglobin increase between Day 0
and Day 28 was similar in the three groups (Table 4). No
gametocytes were observed at enrolment or during follow-up.
Discussion
The risk of recurrent infection at Day 28 after rescue treatment
was significantly lower in the DHAPQ arm as compared to the
quinine and AL arms. However, most infections were new so the
efficacy of the three rescue treatments was not different when
adjusted by genotyping, though there was a tendency towards a
higher efficacy of DHAPQ.
In this study, quinine was administered under direct supervision
and showed excellent efficacy. However, in a recent study carried
out in Uganda, effectiveness of oral quinine was significantly lower
than that of AL [15], a finding probably due to the less than
optimal adherence of the patients to its difficult dosing schedule.
Poor adherence to quinine is a well known problem, mainly due to
the long duration of treatment and the common occurrence of
cinchonism, a phenomenon characterised primarily by tinnitus,
nausea, and dizziness [16–19]. Nevertheless, when administered
under direct supervision as in the current study, quinine’s efficacy
is excellent. High quinine efficacy has similarly been observed in in
vitro studies in Africa [20,21], though resistance has been reported
[22,23].
Recent guidelines advocate for the use of quinine in combina-
tion with clindamycin or a tetracycline [1]. Quinine combined
with tetracycline has been used in Southeast Asia as a second line
treatment for uncomplicated falciparum malaria. When correctly
used, the combination reliably clears parasites and fever.
Nevertheless, treatment adherence is affected by the cinchonism
adverse effects [24,25]. Clindamycin combined with quinine is safe
and effective in adults and children with multidrug-resistant P.
falciparum malaria [25,26]. This combination may be of particular
Figure 2. Trial profile.
doi:10.1371/journal.pone.0053772.g002
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value in children and pregnant women, in whom tetracyclines are
contraindicated [26]. However, the combination is often not
available or affordable in most endemic countries.
The ACTs (AL and DHAPQ) were highly efficacious for the
treatment of recurrent falciparum malaria. AL has shown good
efficacy in repeated treatments of recurrent P. falciparum malaria in
other trials [27,28]. Similarly, DHAPQ has shown good efficacy as
rescue treatment for recurrent P. falciparum infections following 7-
day treatments with combinations of quinine, artesunate or
clindamycin in pregnancy [29]. Patients’ adherence to ACTs is
an equally important factor to ensure treatment efficacy, and to
reduce the risk of selecting resistant parasites. Under conditions of
routine clinical practice, adherence to AL was found to be
suboptimal (64.1%) in Kenya [30], and low (38.7%) in Ethiopia
[31]. In Uganda, full adherence to subsidised over the counter
treatment with AL was only 13.2% [32]. Treatment with ACTs
leads to the rapid clearance of certain symptoms associated with
malaria illness, with the possibility that the patient would
discontinue the treatment prematurely.
The cumulative risk of recurrent parasitaemia was higher after
the second week of follow up. Similar findings have been observed
in areas of intense malaria transmission in Uganda [5,10,14,33–
35] and could be explained by residual drug levels [36,37]. The
risk of recurrent parasitaemia was similar between patients treated
with quinine and AL, and much lower in the DHAPQ group, a
difference mainly due to new infections rather than recrudescences
and explained by differences in pharmacokinetics between quinine
and the non-artemisinin partner drugs. Piperaquine has a much
longer elimination half-life [38] than lumefantrine [39,40], which also
may explain the lower mean parasite density in patients retreated with
AL as they could have had persisting low-level piperaquine activity.
Historically, effective treatment – a vital component of an
effective malaria control strategy- was hampered by the serial
development of resistance to the most commonly used drugs. In
the early 2000 s, the World Health Organization (WHO)
recommended the adoption of ACTs for the treatment of non-
complicated malaria. Most African countries now recommend
ACTs as the first line regimen for treating uncomplicated malaria.
Unfortunately, this effective treatment option is now under threat
as recent reports from South East Asia suggest emerging resistance
to the artemisinin derivatives [41–45]. The enormous public
health impact, if artemisinin resistance were to arrive in Africa, is
compounded by significant reductions in the systematic evaluation
of antimalarial drug treatment efficacy due to lack of funding. It is
reassuring to note that the ACTs (AL and DHAPQ) were highly
efficacious for the treatment of recurrent falciparum malaria.
Table 1. Baseline characteristics of patients with efficacy outcomes.
Characteristic Treatment group*
Quinine (n =111) AL (n =35) DHAPQ (n=72)
Female (%){ 50 (46%) 18 (51%) 33 (46%)
Age in months, median (IQR) 23 (33 -17) 21 (30 -15) 24 (32–18)
Fever (%) 39.00 17.60 39.40
Parasite density per mL, geometric mean
(95% CI)
8107 (5727–11475) 2800 (1370–6314) 6601(4216–10335)
Hemoglobin gm/dL, mean (SD) 10.73 (1.27) 10.57 (1.41) 10.835 (1.34)
Gametocytes at day 0 (%) 0 (0.0) 0 (0.0) 0 (0.0)
*AL =Artemether- lumefantrine. DHAPQ=Dihydroartemisinin piperaquine.
{Fever defined as temperature $37.5uC.
doi:10.1371/journal.pone.0053772.t001
Table 2. WHO treatment outcomes after 28 days of follow-up.
Treatment outcomes Treatment group*
Quinine (n =111) AL (n =35) DHAPQ (n=72)
Lost to follow-up (no treatment outcome)1 0 0
Early treatment failure (ETF) 0 0 0
Late clinical failure (LCF) 31 (28%) 7 (20%) 6 (8%)
Late parasitological failure (LPF) 43 (39%) 14 (40%) 12 (17%)
Adequate clinical and parasitological
response (ACPR)
36 (33%) 14 (40%) 54 (75%)
All failures
Overall 74 (67%) 21 (60%) 18 (25%)
New infection. 62 (56%) 16 (46%) 15 (21%)
Recrudescence 8 (7%) 2 (6%) 1 (1%)
Genotyping unsuccessful 4 (4%) 3 (9%) 2 (3%)
*AL =Artemether- lumefantrine. DHAPQ=Dihydroartemisinin piperaquine.
doi:10.1371/journal.pone.0053772.t002
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More importantly there were no patients with any persisting
parasitaemia at day 3, indicating that delayed parasite clearance, a
phenotype observed in south East Asia has not emerged or
reached this Ugandan site.
This is the first study assessing the appropriate regimen for
rescue therapy after ACT treatment in children. It is apparent that
in areas of intense transmission, the risk of recurrent infection after
quinine treatment, the current recommended second line regimen
for Uganda and many other African countries, was unacceptably
high compared to DHAPQ, which was highly efficacious and
operationally preferable to quinine because of a less intensive
dosing schedule. Therefore, in such settings DHAPQ could be an
ideal second line regimen. In areas of less intense transmission,
where the risk of recurrent infections is low, either DHAPQ or AL
could be preferred to quinine because of their shorter dosing
schedule and better tolerability, hence probably a better compli-
ance. Unfortunately, more than half of the national malaria
control programmes in sub-Saharan Africa still recommend mono-
therapy with oral quinine as second line treatment. Further, in routine
practice the use of oral quinine as a first line treatment seems to be
widespread [10]. Such a practice is not consistent with WHO
guidance and should be urgently addressed to limit the selection
pressure for quinine which is still an option for treating severe malaria.
Generalizability
This study was conducted in a high transmission area and we
believe our findings can be generalisable to other settings in Africa
with similar malaria transmission intensity
Limitations
The desired sample size of 260 on which power calculations
were based could not be attained, affecting the power of the study.
In addition, the number of patients in the AL group was
disproportionately small (n = 35), presumably because failure
within 28 days of DHAPQ in the main study was rare.
Table 3. Estimates of comparative efficacy.
Risk category
28 day risk of treatment failure,
% (95% Confidence Interval) Hazard Ratio (95% CI) p-value
*Unadjusted by genotyping
Quinine vs AL 66.7 (59.0–75.0) vs 60.0 (43.0–76.0) 1.23 (0.78–2.00) 0.398
Quinine vs DHAPQ 66.7 (59.0–75.0) vs 25.0 (15.0–35.0) 3.98 (2.37–6.68) ,0.0001
AL vs DHAPQ 60.0 (43.0–76.0) vs 25.0 (15.0–35.0) 3.32 (1.76–6.26) 0.0002
{Adjusted by genotyping.
Quinine vs AL 7.0 (2.0–12.0) vs 6.0 (0.1–12.0) 1.30 (0.27–6.22) 0.739
Quinine vs DHAPQ 7.0 (2.0–12.0) vs 1.0 (0.1–4.0) 2.09 (0.25–17.43) 0.497
AL vs DHAPQ 6.0 (0.1–12.0) vs 1.0 (0.1–4.0) 1.62 (0.14–18.31) 0.697
*episodes with no outcomes and recurrent parasitemia/malaria caused by non-falciparum species censored.
{episodes with no outcomes, recurrent parasitemia/malaria caused by non-falciparum species, and new P. falciparum infections Censored.
doi:10.1371/journal.pone.0053772.t003
Figure 3. Cumulative risk of recurrent parasitaemia.
doi:10.1371/journal.pone.0053772.g003
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Randomization was dependent on previous treatment, as a result
different groups had different randomization processes. All doses of
the study regimens were given under direct supervision hence
patients who received quinine had a longer interaction with the
health care system. This could have enhanced the likelihood of
detection of recurrent infection in the quinine group when compared
with the other groups. However, all parents were encouraged to
bring their children to the clinic whenever they were unwell.
Overall evidence
Results from this study suggest that quinine is efficacious for the
treatment of recurrent malaria when prescribed and properly
administered. However, the PCR adjusted analysis may not show
a statistically significant difference between quinine and the ACTs
because of the small sample size. Furthermore, quinine effective-
ness may be affected by poor adherence to treatment, particularly
because of the long duration of treatment and of its low
tolerability. Use of an ACT alternative to the first line treatment
is preferable to oral quinine monotherapy because it would be
better tolerated and highly effective against recurrent P.falciparum
malaria. Several highly efficacious ACTs are now available and
can be used as second-line treatments.
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Table 4. Secondary outcomes.
Treatment group
Category. Quinine (n=111) AL (n = 35) DHAPQ (n=72)
Fever clearance*
- Fever on day 11 65 (58.6%) 14 (40.0%) 48 (66.7%)
- Fever on day 2 33 (29.7%) 21 (20.0%) 15 (20.8%)
- Fever on day 3 5 (4.5% 2 (5.7%) 4 (5.6%)
Parasite clearance
- Parasitemia on day 26I1 56 (50.5%) 5 (14.3%) 2 (2.8%)
- Parasitemia on day 3 2 (1.8%) 0 (0.0%) 0 (0.0%)
aAppearance of gametocytes not present on day 0
- Days 1–28 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hemoglobin (Hb) recovery{
- Mean increase (SD) in Hb (g/dL) 1.08 (1.4) 0.93 (1.7) 0.80 (1.7)
Adverse events days 1–28
Cough 67 (60.4%) 20 (57.1%) 47 (65.3%)
Abdominal painI1 0 (0.0%) 0 (0.0%) 5 (2.0%)
Anorexia 13 (11.7%) 3 (8.6%) 12 (16.7%)
Vomiting 1 (0.9%) 2 (5.7%) 3 (4.2%)
Weakness/malaise 4 (3.6%) 0 (0.0%) 1 (1.4%)
Diarrhoea 11 (9.9%) 2 (5.7%) 1 (1.4%)
Serious adverse event 0 (0.0%) 0 (0.0%) 0 (0.0%)
*Subjective fever over previous 24 hours or temperature $37.5uC.
{Change in Hb from day 0 to day 28 or day of clinical failure.
aPatients with gametocytes present on day 0 not included.
6Quinine vs AL, p,0.05.
IQuinine vs DHAPQ, p,0.05.
1AL vs DHAPQ, p,0.05.
doi:10.1371/journal.pone.0053772.t004
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